Patents by Inventor Shubh Sharma
Shubh Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060287332Abstract: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: ApplicationFiled: August 11, 2006Publication date: December 21, 2006Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh SHARMA, Yi-Qun SHI, Kevin BURRIS, Zhijun WU, Papireddy PURMA, Yadi Reddy BONUGA
-
Publication number: 20060287331Abstract: Melanocortin receptor-specific compounds with diamine groups of the general formula and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: ApplicationFiled: August 11, 2006Publication date: December 21, 2006Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh SHARMA, Yi-Qun SHI, Kevin BURRIS, Zhijun WU, Papireddy PURMA, Yadi Reddy BONUGA
-
Publication number: 20060287330Abstract: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b, r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: ApplicationFiled: August 11, 2006Publication date: December 21, 2006Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh SHARMA, Yi-Qun SHI, Kevin BURRIS, Zhijun WU, Papireddy PURMA, Yadi Reddy BONUGA
-
Publication number: 20060240481Abstract: Melanocortin receptor-specific peptide combinatorial libraries for forming metallopeptides and metallopeptide combinatorial libraries are provided for use in biological, pharmaceutical and related applications. The combinatorial libraries are constructed of peptides constructed from naturally occurring amino acids, stereoisomers and modifications of such amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically modified amino acids, or constructs or structures designed to mimic amino acids, in which the peptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.Type: ApplicationFiled: May 22, 2006Publication date: October 26, 2006Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Yiqun Shi, Wei Yang, Hui-Zhi Cai
-
Publication number: 20060111281Abstract: A cyclic peptide of the structural formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, m and p are as defined. Further provided are compositions for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Routes of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.Type: ApplicationFiled: November 9, 2005Publication date: May 25, 2006Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Wei Yang
-
Publication number: 20060083685Abstract: Metallopeptides and metallopeptide combinatorial libraries specific for opioid receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed in a biologically active configuration specific for one or more opioid receptors on complexation of a metal ion-binding portion thereof with a metal ion.Type: ApplicationFiled: December 1, 2005Publication date: April 20, 2006Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Wei Yang, Hui-Zhi Cai
-
Publication number: 20060040324Abstract: A method of making metallopeptide libraries and combinational libraries. The metallopeptide library members name a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The metallopeptides are of the general formula: R1—X—R2 where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R1 and R2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R1 or R2 or both have a structure forming the balance of the conformationally constrained global secondary structure.Type: ApplicationFiled: August 5, 2005Publication date: February 23, 2006Applicant: Palatin Technologies, Inc.Inventor: Shubh Sharma
-
Publication number: 20060014676Abstract: A highly selective melanocortin-4 receptor antagonist cyclic peptide of the formula where R1, R2, R3, R4a, R4b, R5, R6, R7, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.Type: ApplicationFiled: July 5, 2005Publication date: January 19, 2006Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Ramesh Rajpurohit, Annette Shadiack, Yi-Qun Shi, Kevin Burris
-
Publication number: 20060014194Abstract: A highly selective melanocortin-4 receptor antagonist cyclic hexapeptide of the formula where R1, R2, R3a, R3b, R4, R5, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.Type: ApplicationFiled: July 5, 2005Publication date: January 19, 2006Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Ramesh Rajpurohit, Annette Shadiack, Yi-Qun Shi, Kevin Burris
-
Publication number: 20060003386Abstract: Method of making metallopeptide combinatorial libraries and metallopeptides are provided, for use in biological, pharmaceutical and related applications. The combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, and include a metal ion-binding region thereof which includes at least one orthogonal sulfur-protecting group, in which the peptide, peptidomimetic or construct is conformationally fixed on deprotection of the sulfur and complexation of the metal ion-binding region with a metal ion. Thereafter the library members may be screened to select those with the desired specificity and affinity.Type: ApplicationFiled: September 7, 2005Publication date: January 5, 2006Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Yiqun Shi
-
Publication number: 20050282739Abstract: Metallopeptides with a sequence of a biologically active alpha-melanocyte stimulating hormone (?-MSH), gamma-melanocyte stimulating hormone (?-MSH), or bombesin sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side of the n position, or alternatively is substituted for the residue at any position from the three position to the n position, with a metal ion complexed thereto, with any proline (Pro) residue which is either of the two residues on the immediately adjacent N-terminus side of the inserted or substituent residue comprising a nitrogen atom and sulfur atom available for complexation to a metal ion is substituted with a homolog.Type: ApplicationFiled: July 25, 2005Publication date: December 22, 2005Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Yi-Qun Shi, Ramesh Rajpurohit, Hui-Zhi Cai, Margarita Bastos
-
Publication number: 20050222014Abstract: Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and/or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.Type: ApplicationFiled: May 26, 2005Publication date: October 6, 2005Applicant: Palatin Technologies, Inc.Inventors: Lisa Diamond, Dennis Earle, Annette Shadiack, Shubh Sharma, Carl Spana
-
Publication number: 20050181447Abstract: Metallopeptides and metallopeptide combinatorial libraries specific for opioids receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed in a biologically active configuration specific for one or more opioid receptors on complexation of a metal ion-binding portion thereof with a metal ion.Type: ApplicationFiled: May 17, 2002Publication date: August 18, 2005Inventors: Shubh Sharma, Wei Yang, Hui-Zhi Cai
-
Publication number: 20050176728Abstract: Melanocortin receptor-specific compounds of the general formulas and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, L is a linker, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q includes a substituted or unsubstituted aromatic carbocyclic ring, R6, R7, y and z are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration, and optionally with one or two additional ring substituents as defined, which compounds bind to one or more melanocortin receptors and are optionally an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.Type: ApplicationFiled: April 5, 2005Publication date: August 11, 2005Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Yi-Qun Shi, Ramesh Rajpurohit, Zhijun Wu
-
Publication number: 20050164914Abstract: Metallopeptide compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. The metallopeptides include at least one, and preferably two, aromatic amino acid side chain moieties, and are further characterized in that the metallopeptides preferably do not bind or significantly bind to a melanocortin receptor.Type: ApplicationFiled: January 14, 2005Publication date: July 28, 2005Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Annette Shadiack, Wei Yang, Ramesh Rajpurohit
-
Publication number: 20050130988Abstract: A method of modulating energy homeostasis in a mammal without eliciting a sexual response by administration of a therapeutically effective amount of a pharmaceutical composition including a melanocortin receptor compound of the formula: where R1 is a bond or a linker unit including from one to six backbone atoms and an unsubstituted naphthalene group, and L, R2, R3 and Rx are as defined in the specification.Type: ApplicationFiled: January 14, 2005Publication date: June 16, 2005Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Annette Shadiack, Yi- Qun Shi, Zhijun Wu, Ramesh Rajpurohit, Kevin Burris, Papireddy Purma
-
Publication number: 20050124636Abstract: A thienopyrimidine compound of the formula: wherein R1, R2, R3, and R4 are as defined herein, and methods of use of such compounds for the treatment of melanocortin receptor-associated disorders.Type: ApplicationFiled: January 21, 2005Publication date: June 9, 2005Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Yiqun Shi
-
Publication number: 20050124553Abstract: A peptide of the structural formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, m and n are as defined. Further provided are methods for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a peptide of the invention and one or more second sexual dysfunction pharmaceutical agents.Type: ApplicationFiled: January 7, 2005Publication date: June 9, 2005Applicant: Palatine Technologies, Inc.Inventors: Shubh Sharma, Annette Shadiack, Ramesh Rajpurohit, Wei Yang
-
Publication number: 20050038230Abstract: Linear and cyclic peptides are provided specific to one or melanocortin receptors, and which exhibit agonist, antagonist, or mixed agonist-antagonist activity.Type: ApplicationFiled: January 12, 2004Publication date: February 17, 2005Applicant: Palatin Technologies, Inc.Inventors: Shubh Sharma, Annette Shadiack, Wei Yang, Ramesh Rajpurohit
-
Publication number: 20050014193Abstract: The invention provides methods for identification and determination of target-specific folding sites in peptides and proteins, including a method for determining a secondary structure binding to a target of interest within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between two adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence, which includes a minimum of the residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion and two residues on the amino terminus side thereof, is complexed with a metal ion, thereby forming a metallopeptide.Type: ApplicationFiled: June 17, 2003Publication date: January 20, 2005Inventors: Shubh Sharma, Yi-Qun Shi